Abstract:Migraine treatment has evolved into the scientific arena, but it seems still controversial whether migraine is primarily a vascular or a neurological dysfunction. Irrespective of this controversy, the levels of serotonin (5-hydroxytryptamine; 5-HT), a vasoconstrictor and a central neurotransmitter, seem to decrease during migraine (with associated carotid vasodilatation) whereas an i.v. infusion of 5-HT can abort migraine. In fact, 5-HT as well as ergotamine, dihydroergotamine and other antimigraine agents invariably produce vasoconstriction in the external carotid circulation. The last decade has witnessed the advent of sumatriptan and second generation triptans (e.g. zolmitriptan, rizatriptan, naratriptan), which belong to a new class of drugs, the 5-HT1B/1D/1F receptor agonists. Compared to sumatriptan, the second-generation triptans have a higher oral bioavailability and longer plasma half-life. In line with the vascular and neurogenic theories of migraine, all triptans produce selective carotid vasoconstriction (via 5-HT1B receptors) and presynaptic inhibition of the trigeminovascular inflammatory responses implicated in migraine (via 5-HT1D/5-ht1F receptors). Moreover, selective agonists at 5-HT1D (PNU-142633) and 5-ht1F (LY344864) receptors inhibit the trigeminovascular system without producing vasoconstriction. Nevertheless, PNU-142633 proved to be ineffective in the acute treatment of migraine, whilst LY344864 did show some efficacy when used in doses which interact with 5-HT1B receptors. Finally, although the triptans are effective antimigraine agents producing selective cranial vasoconstriction, efforts are being made to develop other effective antimigraine alternatives acting via the direct blockade of vasodilator mechanisms (e.g. antagonists at CGRP receptors, antagonists at 5-HT7 receptors, inhibitors of nitric oxide biosynthesis, etc). These alternatives will hopefully lead to fewer side effects.

The TRPA1 channel in migraine mechanism and treatment

The TRPA1 Ion Channel Mediates Oxidative Stress-Related Migraine Pathogenesis

The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model

TRP channels and migraine

Migraine Treatment: Towards New Pharmacological Targets

Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field

TRPA1 as a drug target--promise and challenges.

Potential treatment targets for migraine: emerging options and future prospects

Molecular basis of TRPA1 regulation in nociceptive neurons. A review

Current insights and therapeutic strategies for targeting TRPV1 in neuropathic pain management

TRPV1-Targeted Drugs in Development for Human Pain Conditions

TRPV1: Receptor structure, activation, modulation and role in neuro-immune interactions and pain

Role of TRPM Channels in Pain States

Novel Therapeutic Targets for Migraine

The TRPM8 channel forms a complex with the 5-HT(1B) receptor and phospholipase D that amplifies its reversal of pain hypersensitivity.

Transient receptor potential vanilloid type 1 and pain development

Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends

TLR4 induced TRPM2 mediated neuropathic pain

Distinctive Drug Binding Sites and Gating Mechanisms of the Nociceptive Ion Channel TRPA1

Voltage-gated calcium channels as potential therapeutic targets in migraine

TRPA1-Mediated Src Family Kinases Activity Facilitates Cortical Spreading Depression Susceptibility and Trigeminovascular System Sensitization